| Allergol Immunopathol (Madr) 1992 Jan-Feb;20(1):35-9
Immunologic clinical evaluation
of a biological response modifier, AM3, in the treatment of
childhood infectious respiratory pathology
[Article in Spanish]
Sanchez Palacios A, Garcia Marrero JA, Schamann F.
Servicio de Alergologia, Hospital Insular, Las Palmas.
To assess the immunoclinical effectiveness of a biological response
immunomodulator, we used AM3 (glycophosphopeptide ), a glucomannan
polysaccharide extracted from the cell wall of a strain of Candida
utilis, in 20 children with asthmatic bronchitis. They received
2 envelopes (1 g) daily for 4 months. The results were compared
with a control group of 20 untreated children with the same
pathology. The following clinical and immunological parameters
were assessed in all of them: cough, dyspnea, expectoration,
frequency and intensity of the bronchospasm, time of administration
of the symptomatic medication, and the delayed cutaneous cells
response by means of the intradermal reaction of 5 antigens
(Trichophyton, Candida albicans, tuberculin, E. coli and bacterial
antigens). In the treated group, the immunoferon (AM3) reduced
the symptoms, the intensity and frequency of the bronchospasm,
and the symptomatic medication (table I, II and III). In basal
conditions, the 40 children presented a state of 75% anergy;
after 4 months of treatment, the treated group experienced a
45% decrease in their anergic situation, variation which was
statistically significant when compared with the control group.
In our 20 treated patients, AM3 behaved like and immunostimulant,
improving the clinical situation and progress in patients with
infectious respiratory disorders. We consider that the immunoferon
constitutes a coadjuvant therapy to bacterial immunotherapy.
- Clinical Trial
- Controlled Clinical Trial